HLA-DO and its role in MHC class II antigen presentation

Frontiers in Immunology

Volumn 4, Issue AUG, 2013, Pages

  Poluektov, Yuri O ^a   Kim, AeRyon ^b   Sadegh Nasseri, Scheherazade ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HLA DM; HLA DO; HLA DR antigens; MHC class II antigen processing; Models for HLA DO function

Indexed keywords

ANTINUCLEAR ANTIBODY; CLASS II ASSOCIATED II PEPTIDE; HLA DM ANTIGEN; HLA DO ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; DOWN REGULATION; GENE EXPRESSION; HUMAN; MUTATION; NONHUMAN; PH; TISSUE DISTRIBUTION; UPREGULATION;

EID: 84883669568     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00260     Document Type: Article

References (58)

1. Klareskog L, Sandgerg-Tragardh L, Rask L, Lindblom JB, Curman B, Peterson PA. Chemical properties of human Ia antigens. Nature (1977) 265(5591):248-51. doi:10.1038/265248a0
2. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol (2011) 11(12):823-36. doi:10.1038/nri3084
3. Larhammar D, Hammerling U, Rask L, Peterson PA. Sequence of gene and cDNA encoding murine major histocompatibility complex class II gene A beta 2. J Biol Chem (1985) 260(26):14111-9.
4. Karlsson L, Surh C, Sprent J, Peterson P. A novel class II MHC molecule with unusual tissue distribution. Nature (1991) 1991:485-8. doi:10.1038/351485a0
5. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J (1996) 15(18):4817-24.
6. Karlsson L, Peleraux A, Lindstedt R, Liljedahl M, Peterson PA. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science (1994) 266(5190):1569-73. doi:10.1126/science.7985028
7. Lindstedt R, Liljedahl M, Peleraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity (1995) 3(5):561-72. doi:10.1016/1074-7613(95)90127-2
8. Deshaies F, Brunet A, Diallo DA, Denzin LK, Samaan A, Thibodeau J. A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM. Proc Natl Acad Sci U S A (2005) 102(18):6443-8. doi:10.1073/pnas.0500853102
9. Chen X, Laur O, Kambayashi T, Li S, Bray RA, Weber DA, et al. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J Exp Med (2002) 195(8):1053-62. doi:10.1084/jem.20012066
10. Fallas JL, Yi W, Draghi NA, O'Rourke HM, Denzin LK. Expression patterns of H2-O in mouse B cells and dendritic cells correlate with cell function. J Immunol (2007) 178(3):1488-97.
11. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol (1997) 9(3):355-64. doi:10.1093/intimm/9.3.355
12. Douek DC, Altmann DM. T-cell apoptosis and differential human leukocyte antigen class II expression in human thymus. Immunology (2000) 99(2):249-56. doi:10.1046/j.1365-2567.2000.00940.x
13. Godfrey DI, Izon DJ, Tucek CL, Wilson TJ, Boyd RL. The phenotypic heterogeneity of mouse thymic stromal cells. Immunology (1990) 70(1):66-74.
14. Berthelot JM, le Goff B, Maugars Y. Thymic Hassall's corpuscles, regulatory T-cells, and rheumatoid arthritis. Semin Arthritis Rheum (2010) 39(5):347-55. doi:10.1016/j.semarthrit.2008.08.010
15. Chen X, Reed-Loisel LM, Karlsson L, Jensen PE. H2-O expression in primary dendritic cells. J Immunol (2006) 176(6):3548-56.
16. Hornell TM, Burster T, Jahnsen FL, Pashine A, Ochoa MT, Harding JJ, et al. Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol (2006) 176(6):3536-47.
17. Fung-Leung WP, Surh CD, Liljedahl M, Pang J, Leturcq D, Peterson PA, et al. Antigen presentation and T cell development in H2-M-deficient mice. Science (1996) 271(5253):1278-81. doi:10.1126/science.271.5253.1278
18. Miyazaki T, Wolf P, Tourne S, Waltzinger C, Dierich A, Barois N, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell (1996) 84(4):531-41. doi:10.1016/S0092-8674(00)81029-6
19. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell (1996) 84(4):543-50. doi:10.1016/S0092-8674(00)81030-2
20. Bikoff EK, Wutz G, Kenty GA, Koonce CH, Robertson EJ. Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice. J Immunol (2001) 166(8):5087-98.
21. Honey K, Forbush K, Jensen PE, Rudensky AY. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M. J Immunol (2004) 172(7):4142-50.
22. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science (1997) 278(5335):106-9. doi:10.1126/science.278.5335.106
23. Liljedahl M, Winqvist O, Surh CD, Wong P, Ngo K, Teyton L, et al. Altered antigen presentation in mice lacking H2-O. Immunity (1998) 8(2):233-43. doi:10.1016/S1074-7613(00)80475-6
24. Perraudeau M, Taylor PR, Stauss HJ, Lindstedt R, Bygrave AE, Pappin DJ, et al. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur J Immunol (2000) 30(10):2871-80. doi:10.1002/1521-4141(200010)30:10<2871::AID-IMMU2871>3.0.CO;2-B
25. Alfonso C, Williams GS, Han JO, Westberg JA, Winqvist O, Karlsson L. Analysis of H2-O influence on antigen presentation by B cells. J Immunol (2003) 171(5):2331-7.
26. Draghi NA, Denzin LK. H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers. Proc Natl Acad Sci U S A (2010) 107(38):16607-12. doi:10.1073/pnas.1004664107
27. Yi W, Seth NP, Martillotti T, Wucherpfennig KW, Sant'Angelo DB, Denzin LK. Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J Clin Invest (2010) 120(4):1324-36. doi:10.1172/JCI40220
28. Gu Y, Jensen PE, Chen X. Immunodeficiency and autoimmunity in H2-O-deficient mice. J Immunol (2013) 190(1):126-37. doi:10.4049/jimmunol.1200993
29. Guce AI, Mortimer SE, Yoon T, Painter CA, Jiang W, Mellins ED, et al. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol (2013) 20(1):90-8. doi:10.1038/nsmb.2460
30. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity (1998) 9(3):377-83. doi:10.1016/S1074-7613(00)80620-2
31. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. Crystal structure of mouse H2-M. Immunity (1998) 9(3):385-93. doi:10.1016/S1074-7613(00)80621-4
32. Pos W, Sethi DK, Call MJ, Schulze MS, Anders AK, Pyrdol J, et al. Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell (2012) 151(7):1557-68. doi:10.1016/j.cell.2012.11.025
33. Pos W, Sethi DK, Wucherpfennig KW. Mechanisms of peptide repertoire selection by HLA-DM. Trends Immunol (2013). doi:10.1016/j.it.2013.06.002. Epub 2013 Jul 10
34. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature (1994) 368(6468):215-21. doi:10.1038/368215a0
35. Sadegh-Nasseri S, Chou CL, Hartman IZ, Kim A, Narayan K. How HLA-DM works: recognition of MHC II conformational heterogeneity. Front Biosci (2012) 4:1325-32. doi:10.2741/S334
36. Sadegh-Nasseri S, Natarajan S, Chou CL, Hartman IZ, Narayan K, Kim A. Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunol Res (2010) 47(1-3):56-64. doi:10.1007/s12026-009-8138-1
37. Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S. HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol (2009) 46(15):3157-62. doi:10.1016/j.molimm.2009.07.001
38. Pashine A, Busch R, Belmares MP, Munning JN, Doebele RC, Buckingham M, et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity (2003) 19(2):183-92. doi:10.1016/S1074-7613(03)00200-0
39. Yoon T, Macmillan H, Mortimer SE, Jiang W, Rinderknecht CH, Stern LJ, et al. Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proc Natl Acad Sci U S A (2012) 109(28):11276-81. doi:10.1073/pnas.1113966109
40. van Ham SM, Tjin EP, Lillemeier BF, Gruneberg U, van Meijgaarden KE, Pastoors L, et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol (1997) 7(12):950-7. doi:10.1016/S0960-9822(06)00414-3
41. Denzin LK, Fallas JL, Prendes M, Yi W. Right place, right time, right peptide: DO keeps DM focused. Immunol Rev (2005) 207:279-92. doi:10.1111/j.0105-2896.2005.00302.x
42. Kropshofer H, Vogt AB, Thery C, Armandola EA, Li BC, Moldenhauer G, et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J (1998) 17(11):2971-81. doi:10.1093/emboj/17.11.2971
43. Poluektov Y, Kim A, Hartman IZ, Sadegh-Nasseri S. HLA-DO as the optimizer of epitope selection for MHC Class II antigen presentation. PLoS ONE (2013) 8(8):e71228. doi:10.1371/journal.pone.0071228
44. Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, et al. A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Nat Med (2010) 16:1333-40. doi:10.1038/nm.2248
45. Natarajan SK, Stern LJ, Sadegh-Nasseri S. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J Immunol (1999) 162(6):3463-70.
46. Chou CL, Sadegh-Nasseri S. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med (2000) 192(12):1697-706. doi:10.1084/jem.192.12.1697
47. Sato AK, Zarutskie JA, Rushe MM, Lomakin A, Natarajan SK, Sadegh-Nasseri S, et al. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem (2000) 275(3):2165-73. doi:10.1074/jbc.275.3.2165
48. Belov K, Lam MK, Hellman L, Colgan DJ. Evolution of the major histocompatibility complex: isolation of class II beta cDNAs from two monotremes, the platypus and the short-beaked echidna. Immunogenetics (2003) 55(6):402-11. doi:10.1007/s00251-003-0598-1
49. Belov K, Lam MK, Colgan DJ. Marsupial MHC class II beta genes are not orthologous to the eutherian beta gene families. J Hered (2004) 95(4):338-45. doi:10.1093/jhered/esh049
50. Soll SJ, Stewart BS, Lehman N. Conservation of MHC class II DOA sequences among carnivores. Tissue Antigens (2005) 65(3):283-6. doi:10.1111/j.1399-0039.2005.00371.x
51. Reynolds RJ, Kelley JM, Hughes LB, Yi N, Bridges SL Jr. Genetic association of htSNPs across the major histocompatibility complex with rheumatoid arthritis in an African-American population. Genes Immun (2010) 11(1):94-7. doi:10.1038/gene.2009.69
52. Yin L, Calvo-Calle JM, Dominguez-Amorocho O, Stern LJ. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives. J Immunol (2012) 189(8):3983-94. doi:10.4049/jimmunol.1200626
53. Denzin LK, Cresswell P. Sibling rivalry: competition between MHC class II family members inhibits immunity. Nat Struct Mol Biol (2013) 20(1):7-10. doi:10.1038/nsmb.2484
54. Porter GW, Yi W, Denzin LK. TLR agonists downregulate H2-O in CD8alpha- dendritic cells. J Immunol (2011) 187(8):4151-60. doi:10.4049/jimmunol.1003137
55. Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MJ, et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol (2009) 182(4):1868-76. doi:10.4049/jimmunol.0802501
56. Dalai SK, Mirshahidi S, Morrot A, Zavala F, Sadegh-Nasseri S. Anergy in memory CD4+ T cells is induced by B cells. J Immunol (2008) 181(5):3221-31.
57. Dalai SK, Khoruzhenko S, Drake CG, Jie CC, Sadegh-Nasseri S. Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Immunol Cell Biol (2011) 89(8):870-81. doi:10.1038/icb.2011.2
58. Dzhagalov IL, Chen KG, Herzmark P, Robey EA. Elimination of self-reactive T cells in the thymus: a timeline for negative selection. PLoS Biol (2013) 11(5):e1001566. doi:10.1371/journal.pbio.1001566